Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann-Alexandre Vano; Réza Elaidi; Mostefa Bennamoun; Christine Chevreau; Delphine Borchiellini; Diane Pannier; Denis Maillet; Marine Gross-Goupil; Christophe Tournigand; Brigitte Laguerre; Philippe Barthélémy; Elodie Coquan; Gwenaëlle Gravis; Nadine Houede; Mathilde Cancel; Olivier Huillard; Philippe Beuzeboc; Laure Fournier; Arnaud Méjean; Xavier Cathelineau; Nicolas Doumerc; Philippe Paparel; Jean-Christophe Bernhard; Alexandre de la Taille; Karim Bensalah; Thibault Tricard; Thibaut Waeckel; Géraldine Pignot; Elena Braychenko; Stefano Caruso; Cheng-Ming Sun; Virginie Verkarre; Guillaume Lacroix; Marco Moreira; Maxime Meylan; Antoine Bougouïn; Letuan Phan; Christelle Thibault-Carpentier; Jessica Zucman-Rossi; Wolf Herman Fridman; Catherine Sautès-Fridman; Stéphane Oudard

doi:10.1016/S1470-2045(22)00128-0

Journal Articles Lancet Oncology Year : 2022

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

(1) , (2, 1) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (1) , (17) , (18) , (19) , (4) , , , , (20) , , , , , , , , , , , , , , , , , ,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Yann-Alexandre Vano

Function : Author

Cancer Research and Personalized Medicine - CARPEM [Paris]

Réza Elaidi

Function : Author

Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie [Paris]

Cancer Research and Personalized Medicine - CARPEM [Paris]

Mostefa Bennamoun

Function : Author

Service d'Oncologie Médicale [Montsouris]

Institut Mutualiste de Montsouris

Christine Chevreau

Function : Author

Institut Claudius Regaud

Delphine Borchiellini

Function : Author

Pôle de Chirurgie Oncologique générale, Gynécologique et Mammaire [Centre Antoine-Lacassagne]

Diane Pannier

Function : Author

Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]

Denis Maillet

Function : Author

Centre de Recherche en Cancérologie de Lyon

Marine Gross-Goupil

Function : Author

Hôpital Saint-André

Christophe Tournigand

Function : Author

CHU Henri Mondor [Créteil]

Brigitte Laguerre

Function : Author

CRLCC Eugène Marquis

Philippe Barthélémy

Function : Author

ChemBioPharm

Elodie Coquan

Function : Author

Centre Régional de Lutte contre le Cancer François Baclesse [Caen]

Gwenaëlle Gravis

Function : Author

Centre de Recherche en Cancérologie de Marseille

Nadine Houede

Function : Author

Centre Hospitalier Universitaire de Nîmes

Mathilde Cancel

Function : Author
PersonId : 808075
ORCID : 0000-0003-1162-214X
IdRef : 23165829X

Centre Hospitalier Régional Universitaire de Tours

Olivier Huillard

Function : Author

Cancer Research and Personalized Medicine - CARPEM [Paris]

Philippe Beuzeboc

Function : Author

Hôpital Foch [Suresnes]

Laure Fournier

Function : Author

Service de Radiologie [CHU HEGP]

Arnaud Méjean

Function : Author

Hôpital Européen Georges Pompidou [APHP]

Xavier Cathelineau

Function : Author

Institut Mutualiste de Montsouris

Nicolas Doumerc

Function : Author

Philippe Paparel

Function : Author

Jean-Christophe Bernhard

Function : Author

Alexandre de la Taille

Function : Author

Résistances Thérapeutiques du Cancer de la Prostate

Karim Bensalah

Function : Author

Thibault Tricard

Function : Author

Thibaut Waeckel

Function : Author

Géraldine Pignot

Function : Author

Elena Braychenko

Function : Author

Stefano Caruso

Function : Author

Cheng-Ming Sun

Function : Author

Virginie Verkarre

Function : Author

Guillaume Lacroix

Function : Author

Marco Moreira

Function : Author

Maxime Meylan

Function : Author

Antoine Bougouïn

Function : Author

Letuan Phan

Function : Author

Christelle Thibault-Carpentier

Function : Author

Jessica Zucman-Rossi

Function : Author

Wolf Herman Fridman

Function : Author

Catherine Sautès-Fridman

Function : Author

Stéphane Oudard

Function : Author

Domains

Life Sciences [q-bio]

Eric HUET : Connect in order to contact the contributor

https://hal.u-pec.fr/hal-04242379

Submitted on : Saturday, October 14, 2023-10:31:26 PM

Last modification on : Thursday, June 20, 2024-5:58:16 PM

Dates and versions

hal-04242379 , version 1 (14-10-2023)

Identifiers

HAL Id : hal-04242379 , version 1
DOI : 10.1016/S1470-2045(22)00128-0

Cite

Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, et al.. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩. ⟨hal-04242379⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS UNIV-AMU UNIV-LYON1 ICR FNCLCC BACLESSE LAMBRET PAOLI_CALMETTES LACASSAGNE MARQUIS UPEC COMUE-NORMANDIE UNIV-COTEDAZUR CRCL UNIV-LILLE CRCM UDL TREPCA

51 View

0 Download

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Altmetric

Share